Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2026 R&D 100 Award Winners
    • 2026 Professional Award Winners
    • 2026 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • Subscribe
    • Video
    • Webinars
    • PharmSci360
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

NCSA Reveals Promising Diagnostics for Detecting Latent Tuberculosis

By National Center for Supercomputing Applications | March 15, 2019

A collaboration between the National Center for Supercomputing Applications (NCSA) at the University of Illinois, Mayo Clinic, and the University of Michigan are introducing a new machine-learning-driven approach to LTBI diagnostics. While leveraging a high throughput detection technology and powerful bioinformatics, this approach aims to reveal multi-marker signatures for LTBI diagnosis and risk stratification.

Latent tuberculosis infections (LTBI) are estimated in nearly one-quarter of the world’s population, and of those immunocompetent and infected roughly 10 percent will proceed to active tuberculosis (TB). While current diagnostics cannot definitively identify LTBI and provide no insight into reactivation risk, there remains an unmet diagnostic challenge of global significance.

This approach is enabled through an individualized normalization procedure that allows disease-relevant biomarker signatures to be revealed in a basal immune response. Specifically, cytokines (cell signaling proteins) were detected using silicon photonic sensor arrays and multidimensional data correlation of individually-normalized immune responses revealed signatures important for LTBI status.

“The difficulties of extracting biomarker signatures from LTBI data is primarily analytical because these data belong to a class of problems where the number of measured predictors is larger than the number of samples in the study,” said Heather Robison, a former postdoctoral scholar at University of Michigan who completed her Ph.D. at the University of Illinois, “we have employed an approach from machine learning based on random forest, Boruta, which has shown success in biomarker signature extraction particularly for this type of data set.”

Boruta, a feature selection method, uses a Random Forest classification algorithm with shadow features, which are data that are random by design and act as a threshold above which real features that are truly important emerge. This approach removes biomarkers that do not show any correlation with specific LTBI related diagnoses, while retaining all features with importance above the noise, thereby avoiding the elimination of relevant features.

“The VI-Bio group has developed an environment that incorporates approaches from the domain of machine learning for feature selection, feature ranking, and predictive modeling which was utilized for this project,” said Loretta Auvil, data scientist. “We strive to identify the definitively important features from the large number of features that have been gathered.”

In addition to Boruta analysis, each of the individually selected features were further statistically evaluated to first ensure their differential diagnostic capacity relative to LTBI status.

“A multi-array test can provide a more detailed, disease-specific glimpse into patient’s infection and likely outcome,” said Ryan Bailey, professor in Department of Chemistry at the University of Michigan and an author on the study. “Using a precision medicine approach reveals previously obscured diagnostic signatures and reactivation risk potential.”

Since 2010 the Mayo Clinic & Illinois Alliance for Technology-Based Healthcare has launched numerous collaborations that have grown and continued for years. “Tackling these hard problems takes strong commitments from a diverse group of people,” said Colleen Bushell, senior research scientist and lead of NCSA’s VI-Bio group. Thanks to the Alliance’s funding and efforts to bring together innovative teams, this collaboration has leveraged NCSA’s expertise in machine-learning and computation to make strides in precision healthcare using big data to improve diagnostic treatments and early detection, all while keeping patients at the center of its focus.

These results demonstrate a powerful combination of multiplexed biomarker detection technologies, precision immune normalization, and feature selection algorithms that revealed positively correlated multi-biomarker signatures for LTBI status and reactivation risk stratification from a relatively simple blood-based assay.

Learn more about the study, published in Integrated Biology here.

Related Articles Read More >

Screenshots of HuBMAP Data Portal visualizations of seqFISH, imaging mass cytometry, MIBI and CODEX/PhenoCycler data, showing fluorescent tissue images and cell clusters.
Harvard-led team says NIH-funded healthy-tissue atlas is AI-ready, but its paper warns it’s not fully representative
Abstract of modern high tech internet data center room with rows of racks with network and server hardware. 3d rendering
A startup says it found hidden memory behavior in NVIDIA GPUs and is building a security layer around it
Bioptimus launches massive patient data atlas to train its biology AI
Basecamp Research partners with Anthropic, NVIDIA to build the world’s largest genomic database
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.

R&D World Digital Issues

Fall 2026 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

R&D 100 Awards
Research & Development World
  • Subscribe to R&D World Magazine
  • Sign up for R&D World’s newsletter
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2026 R&D 100 Award Winners
    • 2026 Professional Award Winners
    • 2026 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • Subscribe
    • Video
    • Webinars
    • PharmSci360
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE